sonomabio.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $365.1MM
Sonoma Biotherapeutics is a biotech company focused on the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/04/2021 | Series B-1 | $147.78MM | $xx.xx | $732.39MM | Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron | |
Price per Share
$xx.xx
Shares Outstanding
49,849,130
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron
|
||||||
08/04/2021 | Series B | $147.22MM | $xx.xx | $732.39MM | Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron | |
Price per Share
$xx.xx
Shares Outstanding
74,494,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron
|
||||||
09/30/2020 | Series A | $70.1MM | $xx.xx | $116.83MM | Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, JDRF T1D Fund | |
Price per Share
$xx.xx
Shares Outstanding
70,100,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, JDRF T1D Fund
|